D esmoplastic small round cell tumors (DSRCTs) are rare primitive neoplasms that have an aggres sive clinical course. Despite multiple modalities of treatment, these tumors remain incurable and have poor long-term survival rates. They were first described in 1989 by Gerald and Rosai.
D esmoplastic small round cell tumors (DSRCTs) are rare primitive neoplasms that have an aggres sive clinical course. Despite multiple modalities of treatment, these tumors remain incurable and have poor long-term survival rates. They were first described in 1989 by Gerald and Rosai. 3 These tumors are more common in males and usually present in adolescence or early adult hood. There are no reliable biomarkers or specific radio logical signs for their diagnosis; however, recent advances in molecular biology and immunohistochemistry allow re liable diagnosis through examination of a biopsy specimen in most cases. Cytogenetic analysis in DSRCTs has shown a specific chromosomal abnormality, t(11;22)(p13;q12), as a result of gene translocation and rearrangement of the genes for Ewing's sarcoma (EWS) and Wilms tumor 1 (WT1). The gene fusion of EWS-WT1 is described to be specific to DSRCTs. a suprasellar mass. The tumor caused panhypopituitarism and visual field defects as a result of optic chiasm com pression in a young man and had a fatal outcome because of progressive disease.
case report

History and Examination
A 27-year-old man was referred to the endocrinology clinic with a history of excessive tiredness, lethargy, and loss of libido. He had a medical history of depression and had been treated with fluoxetine. His secondary sexual characteristics were normal, but he had a reduced testicu lar volume (12 ml) bilaterally. There were no clinical fea tures to suggest the presence of acromegaly or Cushing's disease. His visual fields were full to confrontation, and no neurological deficits were identified during clinical ex amination on his initial visit. Blood tests revealed panhy popituitarism with the following parameters: testosterone < 0.4 nmol/L (normal range 8.5-29 nmol/L), undetectable luteinizing hormone and folliclestimulating hormone, random cortisol 14 nmol/L, thyroid-stimulating hormone < 0.01 mIU/L (normal range 0.4-4.5 mIU/L), free T4 9.3 pmol/L (normal range 10-23 pmol/L), insulin-like growth factor-I 11 nmol/L (age and sex-adjusted normal range 15-47 nmol/L), random growth hormone 0.2 μg/L, and prolactin 835 mIU/L (normal < 350 mIU/L). The patient's treatment regimen began with replacement doses of hy drocortisone followed by levothyroxine. Gadoliniumen hanced MRI showed a large suprasellar heterogeneously enhancing mass extending upward into the third ventricle, compressing the optic chiasm, and downward to the pi tuitary fossa (Fig. 1A) . No abnormality was detected in the rest of the brain. The patient was referred for urgent neurosurgical and ophthalmic assessments, but he failed to attend these appointments as well as further endocrine followup appointments.
Operation
A year later, the patient presented to the emergency de partment with worsening frontal headaches, drowsiness, and bitemporal hemianopia. Repeat MRI demonstrated a significant increase in the size of the suprasellar tumor (Fig. 1B) . He was admitted to the neurosurgical unit, un derwent a right frontoparietal craniotomy, and had near total removal of the tumor (Fig. 1C) . He developed central diabetes insipidus postsurgery and began treatment with desmopressin while continuing with hydrocortisone and levothyroxine replacement therapy.
Pathology Findings
Histological examination revealed a tumor consisting of nests and cords of fairly uniform tumor cells charac terized by hyperchromatic nuclei and indistinct cytoplasm distributed in a desmoplastic stroma ( Fig. 2A) . Some tu mor cell nests appeared obliterated by dystrophic calci fication. Mitotic activity and necrosis were discernible in the cell nests. Immunohistochemical staining revealed strong diffuse immunopositivity for cytokeratin CAM 5.2, vimentin, and desmin (Fig. 2B) . Desmin (Fig. 2B ) and placental alkaline phosphatase (PLAP) (Fig. 2C ) stain ing demonstrated strong paranuclear dot to curvilinear positivity in a significant proportion of tumor cells. A subset of tumor cells that was dispersed through the nests also showed positivity for neurofilament protein and fo cal weak staining with neuron-specific enolase (Fig. 2D) . Strong but patchy positivity was seen with epithelial mem brane antigen (EMA), with focal positivity for CK7 and CK20. The tumor cells were negative for chromogranin, synaptophysin, CD56, CD99, S100, and WT-1 (aminoterminal antibody used). Fluorescent in situ hybridization (FISH) analysis using the EWSR1 gene probe (Vysis LSI EWSR1 Dual Color Break Apart Probe, Abbott Molecu lar) demonstrated EWSR1 gene arrangement in multiple tissue areas. Reverse transcription polymerase chain reac tion (RT-PCR) analysis with DNA sequencing of the PCR product confirmed an EWS exon 8/WT1 exon 8 transloca tion and EWS-WT1 transcript corroborating the diagnosis of DSRCT. Thus, the cytoarchitectural features, immuno phenotype, and genotype were consistent with a diagnosis of DSRCT.
Radiology Findings
Immediate postoperative CT scans of the thorax, ab domen, and pelvis showed no evidence of a primary ma lignancy elsewhere, supporting that the DSRCT in the suprasellar region represented a primary CNS tumor and not a metastatic deposit. An MRI scan obtained 4 months after craniotomy revealed rapid expansion of the suprasel lar tumor remnant measuring 4.5 × 3.5 cm (Fig. 1D) . The patient started receiving fractionated conformal radiother apy, but treatment was discontinued after 1 week because of general deterioration in his condition. A repeat CT scan of the thorax, abdomen, and pelvis showed extensive met astatic disease involving mediastinal, subcarinal, and hilar lymph nodes, causing occlusion of the right main bron chus and right pulmonary infiltrates. No intraabdominal masses or lymph nodes were identified, and the appear ances of the liver, spleen, and adrenal glands were normal. The histological results of a fine-needle aspirate obtained from a cervical lymph node were once again consistent with DSRCT. Palliative chemotherapy was considered; however, the patient's clinical condition deteriorated rap idly and he died 20 months after his initial presentation.
discussion
An intracranial DSRCT presenting as a suprasellar mass poses a major challenge in diagnosis and manage ment. A tissue biopsy is essential to differentiate this lesion from other suprasellar tumors, such as invasive pituitary adenomas, craniopharyngiomas, gliomas, meningiomas, and metastases. Although the majority of DSRCTs have characteristic histological features, a significant propor tion can exhibit a wide range of morphological features. The main differential diagnoses for these tumors pre senting in the CNS based on histological findings should include medulloblastomas, atypical teratoid/rhabdoid tu mors, and primitive neuroectodermal tumors. 7 Immuno cytochemistry and molecular genetics help to distinguish DSRCTs reliably from other tumors.
Cytogenetic analysis in DSRCTs has shown a specific chromosomal abnormality, t(11;22)(p13;q12), as a result of gene translocation and rearrangement of the genes for
EWS and WT1.
4 This can be demonstrated by RTPCR or by FISH. The authors of a large series of DSRCTs re ported a significant variation in clinical features, cytology, and immunoreactivity, but the gene fusion EWS-WT1 was consistently distinctive to this tumor.
2 Histological ex amination, immunocytochemistry, and genotyping in our case demonstrated features typical of a DSRCT, which are quite distinct from the other tumors mentioned above.
The rare occurrence of these tumors makes the study of different treatment modalities and their impact on sur vival very difficult. Kushner et al. 5 showed that intense al kylator-based therapy with the P6 protocol (cyclophospha mide, doxorubicin, vincristine, ifosfamide, and etoposide) improved remission rates in patients with intraabdominal or pelvic DSRCTs. In that study, 7 of 12 patients achieved a shortterm remission, and 4 had complete remission for over 1 year. Quaglia and Brennan 9 studied 40 patients, 27 of whom had intraabdominal tumors. Overall survival at 3 years from diagnosis was 29%, and induction chemothera py with P6 protocol and gross-total resection of the tumor were associated with improved survival. Lal et al. 6 showed that multimodality treatment improved the survival rate in a study of 66 patients with predominantly intraabdominal tumors. The 3-year survival rate was 55% in patients re ceiving induction chemotherapy (P6 protocol) combined with surgical debulking and radiotherapy.
Systematic review of the literature yielded only 5 cases of intracranial DSRCTs. Evaluation of presenting symp toms, pathological findings, management, and outcome of these limited cases shows the aggressive nature of these tumors despite multiple modalities of treatment (Table 1) . Tison et al. 10 reported on a 24-year-old man with poste rior cranial fossa tumor adherent to the tentorium. This patient underwent a partial excision of the tumor and re ceived 3 cycles of chemotherapy (PCNU cisplatin and V16) combined with radiotherapy and was receiving intra cranial methotrexate at the time the study was published. There are no details published on longterm survival for this patient. Neder et al. 7 reported on 2 cases of DSRCT. The first patient was a 37-year-old man with a cerebel lopontine angle tumor. He underwent subtotal resection and stereotactic irradiation but the disease progressed to spinal metastases 6 months later. He died 2 years after diagnosis despite receiving wholebrain and wholespine radiotherapy and chemotherapy. The second patient was a 39-year-old man, with multiple lesions in the left cerebel lar hemisphere and spinal leptomeninges, who presented with cauda equina syndrome. He underwent surgical de compression of the spinal cord and conus medullaris fol lowed by radiotherapy and 3 courses of chemotherapy. He developed further posterior fossa and spinal axis lesions 27 months after diagnosis.
Yachnis et al. 11 described a possible DSRCT in a 9-month-old girl with an aggressive posterior cranial fossa tumor requiring the placement of a ventriculoperitoneal shunt for obstructive hydrocephalus. She required a sec ond craniotomy for tumor debulking surgery 18 months later despite intensive chemotherapy. Long-term survival details of this patient are not available. Bouchireb et al. were not diagnostic of DSRCT but had the characteristic EWS-WT1 translocation. This patient underwent excision of the mass followed by P6 protocol chemotherapy 5 and focal conformal irradiation of tumor bed at 54 Gy. She was reported to be free of the disease 18 months after di agnosis.
In summary, we have described the first case of an in tracranial DSRCT presenting as a suprasellar mass, caus ing panhypopituitarism and bitemporal hemianopia in a young man who died of progressive disease. Despite mul timodality treatment, the aggressive behavior of this tu mor was similar to DSRCTs arising from the peritoneal cavity and the few rare intracranial cases. Failure to attend followup outpatient appointments and possible noncom pliance with treatment may have also contributed to the poor prognosis in our patient. It is important to include DSRCTs in the differential diagnosis of an unusual supra sellar mass in young adults. Once the tumor is identified histologically, grosstotal resection and radical postopera tive treatment involving radiotherapy, chemotherapy, and close surveillance are required because of its potential for an aggressive clinical course.
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